GRACE :: Lung Cancer
Denise Brock

Targeted Therapies Patient Forum September 2017 Speaker Highlight – Shirish M. Gadgeel, MD

***Speaker Highlights***

for full faculty bio’s, please visit our FACULTY page


 Learn about Shirish M. Gadgeel, MD

 

Dr. Shirish Gadgeel is the co-leader of the Molecular Therapeutics Program of the Karmanos Cancer Institute (KCI). Dr. Gadgeel has conducted and participated in many lung cancer specific trials and has also been a principal investigator of a Southwest Oncology Group trial, S0528 and NCI protocol 7389. He has engaged in many epidemiologic studies in the field of lung cancer, publishing on features of lung cancer in African-Americans and young patients. He is currently the principal investigator of multi-PI R21 to identify ‘driver’ genetic alterations in African-American lung cancer patients. 

Dr. Gadgeel’s clinical research experience spans 14 years. He is a member of the Steering Committees of the Early Therapeutics Committee and Lung Cancer Committee of Southwest Oncology Group (SWOG). He sits on the editorial boards of the medical journals, Clinical Lung Cancer and Cancer, and a reviewer for many others including Clinical Cancer Research, Lancet Oncology and the Journal of Thoracic Oncology. Dr. Gadgeel was awarded by the NCI the Cancer Clinical Investigator Team Leadership Award in 2012.

  


Here is the first part of Dr. Gadgeel’s discussion from last year’s Targeted Therapies Patient Forum in Aurora, Colorado.  

 

Please feel free to offer comments and raise questions in our Discussion Forums.


Targeted Therapies in Lung Cancer Patient Forum

September 16, 2017

Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center

See below for our growing list of topics and presenters!  

Register at cancerGRACE.org | Agenda is subject to change

8:30 – 10:00 am        The Many Faces of Progression
Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy
Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope
10:30 – noon       
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy? 
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West

BREAKOUT SESSIONS

1:00 – 2:30 pm     
 
Presentations by Lung Cancer Sub-type
*Available treatment options 
*Acquired resistance: How do you pick your next treatment? 
ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient

BREAKOUT SESSIONS

2:50 – 4:00 pm     
 
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center
Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program
Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger

 Please feel free to offer comments and raise questions in our Discussion Forums.

 GRACE would like to thank the following companies for their support of this forum:

B-I for web           
Guardant

 

 


Dr West

My Top 10 ASCO 2017 Lung Cancer Presentations

Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging on Chicago for the American Society for Clinical Oncology (ASCO) annual conference, the biggest cancer meeting of the year. There is far too much happening for people to be able to see everything, but fortunately people will be providing summaries on Twitter (follow me at @JackWestMD), various blogs (I’m writing commentary for Medscape), and lots of online and print news outlets.  GRACE will be doing an annual “highlights” video series in just a few weeks, but in the meantime, here is a preview of the top 10 presentations in lung cancer from my perspective, primarily thinking about likely impact on clinical practice for thoracic oncology patients:

JW Top 10 LC presentations for ASCOJW Top 10 LC presentations for ASCO pt 2


Dr West

New FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think It’s a Poor Choice for Initial Treatment

The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The agent Zykadia (ceritinib), a “second generation” ALK inhibitor that is more effective than Xalkori (crizotinib) in lab models of ALK-positive NSCLC, and the new approval was for Zykadia as first line treatment for ALK-positive lung cancer, a setting where we have historically favored Xalkori since it was approved in 2011. . Despite the FDA approval for ceritinib, I don’t believe it should be favored as a first line therapy for ALK-positive patients. Why would I not favor it?

Continue reading


Denise Brock

Targeted Therapies Patient Forum September 2017 Speaker Highlight – John Cherol

***Speaker Highlights***

for full faculty bio’s, please visit our FACULTY page


 Learn about John Cherol, EGFR patient

 

John Cherol was diagnosed in January 2016 with Stage IV EGFR+ lung cancer at the age of 28. He started Gilotrif (afatinib) and acquired resistance after 14 months. Luckily a blood test showed he developed the t790m mutation and he started Tagrisso in April of this year. He’s also been treated for nine brain mets with Gamma Knife at the Cleveland Clinic.

John is a graduate of Youngstown State University with a bachelor’s degree in computer forensics.  He currently works as a Senior Cyber Security Analyst in Pittsburgh, PA. He got engaged shortly after his diagnosis to his fiancé, Kristine, who he met in 2014. They’re actively planning their September 9th wedding and a honeymoon to Iceland. Thanks to targeted therapy, John has been able to continue some of the hobbies he loves most like camping and kayaking. He hopes to help change the face of lung cancer and enjoy many more evening walks with Kristine and their rescue dog Liam.

 

 


 

Please feel free to offer comments and raise questions in our Discussion Forums.


Targeted Therapies in Lung Cancer Patient Forum

September 16, 2017

Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center

See below for our growing list of topics and presenters!  

Register at cancerGRACE.org | Agenda is subject to change

8:30 – 10:00 am        The Many Faces of Progression
Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy
Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope
10:30 – noon       
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy? 
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West

BREAKOUT SESSIONS

1:00 – 2:30 pm     
 
Presentations by Lung Cancer Sub-type
*Available treatment options 
*Acquired resistance: How do you pick your next treatment? 
ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient

BREAKOUT SESSIONS

2:50 – 4:00 pm     
 
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center
Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program
Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger

 Please feel free to offer comments and raise questions in our Discussion Forums.

 GRACE would like to thank the following companies for their support of this forum:

B-I for web           
Guardant

 

 


Denise Brock

Targeted Therapies Patient Forum September 2017 Speaker Highlight – Janet Freeman Daily

***Speaker Highlights***

for full faculty bio’s, please visit our FACULTY page


 Learn about Janet Freeman-Daily, ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger

 

Janet Freeman-Daily is a writer, science geek, and lung cancer patient/activist. She received a diagnosis of advanced non-small cell lung cancer in May 2011 which became metastatic despite chemotherapy and radiation.  After learning about genomic testing and precision medicine in online patient communities, she joined a clinical trial for ROS1-positive lung cancer and has had no evidence of disease for over four years.

After twenty years in aerospace systems engineering, Janet is now a full-time patient activist who translates the experience and science of lung cancer treatment and research to improve outcomes and quality of life for lung cancer patients. She co-moderates the Lung Cancer Social Media (#LSCM) Chat on Twitter as @JFreemanDaily, blogs at grayconnections.net, and is one of the leaders of the Global ROS1 Initiative. She has spoken at events and on videos for lung cancer advocacy organizations, hospitals and cancer research centers, oncology conferences, President’s Cancer Panel workshops, and the National Cancer Institute. 

 


 

To see more Janet Freeman-Daily on GRACE, please visit this link
Please feel free to offer comments and raise questions in our Discussion Forums.


Targeted Therapies in Lung Cancer Patient Forum

September 16, 2017

Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center

See below for our growing list of topics and presenters!  

Register at cancerGRACE.org | Agenda is subject to change

8:30 – 10:00 am        The Many Faces of Progression
Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy
Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope
10:30 – noon       
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy? 
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West

BREAKOUT SESSIONS

1:00 – 2:30 pm     
 
Presentations by Lung Cancer Sub-type
*Available treatment options 
*Acquired resistance: How do you pick your next treatment? 
ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient

BREAKOUT SESSIONS

2:50 – 4:00 pm     
 
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center
Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program
Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger

 Please feel free to offer comments and raise questions in our Discussion Forums.

 GRACE would like to thank the following companies for their support of this forum:

B-I for web           
Guardant

 

 


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Subscribe to the GRACEcast Podcast on iTunes

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243